Who dares stay in hepatitis C as another drug dies?
This article was originally published in Scrip
Merck & Co has informed the US FDA that it will stop selling its hepatitis C drug Victrelis (boceprevir) in the US by the end of this year.
You may also be interested in...
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.